Compare Nano Dimension Ltd - ADR (NNDM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nano Dimension Ltd - ADR vs TransMedics Group Inc — how do they compare? Nano Dimension Ltd - ADR trades at $1.55 (market cap $328.52M), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 8.3× Nano Dimension Ltd - ADR's market cap, and Nano Dimension Ltd - ADR is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nano Dimension Ltd - ADR for 43 Days and TransMedics Group Inc for 24 Days on average.
| NNDM | TMDX | |
|---|---|---|
Market Cap | $328.52M | $2.74B |
Volume | 1,160,945 | 949,331 |
Sector | Technology | Health |
52-Week High | $2.14 | $150.42 |
52-Week Low | $1.21 | $61.99 |
Typical Hold Time | 43 Days | 24 Days |
Enterprise Value | -$76.33M | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nano Dimension (NNDM) trades at $1.55 with no recent price movement, reflecting a bearish technical signal. The company shows revenue growth from $102M in 2025 to $121M in 2026 but continues to report significant net losses, with a -135.18% net income margin. Recent strategic actions include cost-saving initiatives and leadership changes, with the sale of MarkForged expected to close in late 2026. Cash flow remains volatile, with 2025 showing a net cash outflow of $112M.
The outlook remains challenging due to persistent losses and cash burn, though revenue growth and asset sales provide some stability. Investment opportunities exist if cost reductions translate to profitability, but risks include ongoing operational losses and competitive pressures in the industrial sector. The stock's low valuation multiples may attract value investors, but sustained profitability is needed for long-term upside.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
